Value in Oncology, an Interview with Marty Neltner

The 2025 National ICE-T Symposium gave oncology experts an opportunity to share ideas regarding the administration of cellular therapies.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Pre-planned interim results from the phase EPCORE FL-1 trial supported the FDA granting priority review to epcoritamab with rituximab and lenalidomide in relapsed/refractory FL.

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Data from the PANOVA-3 trial may support the concomitant use of TTFields plus standard of care in solid tumors across different therapeutic settings.